Biofrontera AG – Product Pipeline Review – 2014

27 pages report Published in
Pharmaceuticals
Publisher: Global Markets Direct

arrowFor This Report

Global Markets Direct’s, ‘Biofrontera AG Product Pipeline Review 2014′, provides an overview of the Biofrontera AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biofrontera AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biofrontera AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biofrontera AG’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biofrontera AG’s pipeline products

Reasons to buy

  • Evaluate Biofrontera AG’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biofrontera AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biofrontera AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biofrontera AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biofrontera AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biofrontera AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Biofrontera AG Snapshot 4
Biofrontera AG Overview 4
Key Information 4
Key Facts 4
Biofrontera AG - Research and Development Overview 5
Key Therapeutic Areas 5
Biofrontera AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Biofrontera AG - Pipeline Products Glance 9
Biofrontera AG - Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Biofrontera AG - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Biofrontera AG - Drug Profiles 12
aminolevulinic acid hydrochloride 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
BF-Derm-1 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
BF-1 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Biofrontera AG - Pipeline Analysis 17
Biofrontera AG - Pipeline Products by Target 17
Biofrontera AG - Pipeline Products by Route of Administration 18
Biofrontera AG - Pipeline Products by Molecule Type 19
Biofrontera AG - Pipeline Products by Mechanism of Action 20
Biofrontera AG - Recent Pipeline Updates 21
Biofrontera AG - Dormant Projects 23
Biofrontera AG - Discontinued Pipeline Products 24
Discontinued Pipeline Product Profiles 24
riluzole 24
Biofrontera AG - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Biofrontera AG, Key Information 4
Biofrontera AG, Key Facts 4
Biofrontera AG - Pipeline by Indication, 2014 6
Biofrontera AG - Pipeline by Stage of Development, 2014 7
Biofrontera AG - Monotherapy Products in Pipeline, 2014 8
Biofrontera AG - Phase III, 2014 9
Biofrontera AG - Phase II, 2014 10
Biofrontera AG - Phase I, 2014 11
Biofrontera AG - Pipeline by Target, 2014 17
Biofrontera AG - Pipeline by Route of Administration, 2014 18
Biofrontera AG - Pipeline by Molecule Type, 2014 19
Biofrontera AG - Pipeline Products by Mechanism of Action, 2014 20
Biofrontera AG - Recent Pipeline Updates, 2014 21
Biofrontera AG - Dormant Developmental Projects,2014 23
Biofrontera AG - Discontinued Pipeline Products, 2014 24
Biofrontera AG, Subsidiaries 25

List of Figures

Biofrontera AG - Pipeline by Top 10 Indication, 2014 6
Biofrontera AG - Pipeline by Stage of Development, 2014 7
Biofrontera AG - Monotherapy Products in Pipeline, 2014 8
Biofrontera AG - Pipeline by Top 10 Target, 2014 17
Biofrontera AG - Pipeline by Top 10 Route of Administration, 2014 18
Biofrontera AG - Pipeline by Top 10 Molecule Type, 2014 19
Biofrontera AG - Pipeline Products by Top 10 Mechanism of Action, 2014 20

Related Reports

  • Intra-Cellular Therapies, Inc. – Product Pipeline Review – 2015Global Markets Direct's, ‘Intra-Cellular Therapies, Inc. Product Pipeline Review 2015', provides an overview of the Intra-Cellular Therapies, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Intra-Cellular Therapies, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and […]
  • Vanda Pharmaceuticals Inc. – Product Pipeline Review – 2014Global Markets Direct's, ‘Vanda Pharmaceuticals Inc. Product Pipeline Review 2014', provides an overview of the Vanda Pharmaceuticals Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vanda Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule […]
  • Panmira Pharmaceuticals, LLC. – Product Pipeline Review – 2014Global Markets Direct's, ‘Panmira Pharmaceuticals, LLC. Product Pipeline Review 2014', provides an overview of the Panmira Pharmaceuticals, LLC.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Panmira Pharmaceuticals, LLC.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and […]
  • Vical Incorporated – Product Pipeline Review – 2015Global Markets Direct's, ‘Vical Incorporated Product Pipeline Review 2015', provides an overview of the Vical Incorporated's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews […]
  • NeoStem, Inc. – Product Pipeline Review – 2014Global Markets Direct's, ‘NeoStem, Inc. Product Pipeline Review 2014', provides an overview of the NeoStem, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of NeoStem, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and […]